Ifp Advisors, Inc Coherus Bio Sciences, Inc. Transaction History

Ifp Advisors, Inc

$2.91 Billion
Q4 2024

A detailed history of Ifp Advisors, Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 224 shares of CHRS stock, worth $239. This represents 0.0% of its overall portfolio holdings.

Number of Shares

224

Holding current value

$239

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$0.67 - $1.71 $150 - $383	224 New	224 $0
Q4 2022 Feb 07, 2023	BUY	$5.69 - $10.07 $5,690 - $10,070	1,000 New	1,000 $16,000
Q4 2021 Jan 12, 2022	BUY	$15.81 - $18.99 $837 - $1,006	53 New	53 $1,000
Q3 2021 Oct 06, 2021	SELL	$12.68 - $17.79 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$12.95 - $15.41 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	SELL	$14.42 - $21.39 $259 - $385	-18 Closed	0 $0
Q4 2020 Jan 25, 2021	SELL	$16.56 - $18.94 $281 - $321	-17 Reduced 48.57%	18 $0
Q3 2020 Oct 29, 2020	BUY	$17.41 - $19.89 $609 - $696	35 New	35 $0
Q2 2020 Aug 05, 2020	SELL	$14.43 - $19.16 $2,323 - $3,084	-161 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$11.67 - $22.53 $245 - $473	21 Added 15.0%	161 $3,000
Q3 2019 Nov 07, 2019	BUY	$16.3 - $23.37 $2,282 - $3,271	140 New	140 $3,000

Others Institutions Holding CHRS

# of Institutions

130

Shares Held

67.8M

Call Options Held

1.68M

Put Options Held

91.8K

Black Rock Inc. New York, NY

11.8M
Shares

$12.6 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.2M
Shares

$11.9 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

5.28M
Shares

$5.65 Million
0.02% of portfolio
Rubric Capital Management LP New York, NY

5.26M
Shares

$5.63 Million
0.12% of portfolio
Tang Capital Management LLC San Diego, CA

3.65M
Shares

$3.91 Million
0.38% of portfolio

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $83.2M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account